Jen Porcelli

@BiotechCLin @avidresearch You created a Twitter account solely to track Biohaven? That's dedication! Attending any upcoming sell-side conferences? Happy to meet!

@avidresearch YES! I wrote a whole substack article about it. I even wrote an activist letter. To IR. This account was created solely because their IR team ignored me. I now got their IR head Jen follow my account and I am sure my write up was given to the management. Give up holding i

So do we like $BHVN after R&D day?

From NYSE: @biohaven CEO Vlad Coric recaps last week's R&D Day and walks us through the company's pipeline. $BHVN Full video: biotechtv.com/post/biohaven-…

A brand new drug from $BHVN promises to promote muscle gain in patients taking GLP-1 obesity drugs CEO Vlad Coric breaks down the treatment's latest clinical trial results and how soon it could impact patients and the weight loss space:

@Biohazard3737 The T Alfa compound also engages Activin - please refer to Biohaven's latest slide deck and feel free to reach out if you want to connect with our team

SF Healthcare Week: @biohaven has been developing a myostatin inhibitor to increase muscle mass in SMA patients. They believe it also has utility for the obesity market. It's one of the many programs 'New Biohaven' has been developing. $BHVN Full video: biotechtv.com/post/biohaven-…

@US_FDA recently issued a Refuse to File letter to @Biohaven regarding its New Drug Application (NDA) for troriluzole to treat SCA3. NAF calls on the FDA to apply regulatory flexibility & accept the NDA for troriluzole. Read our full statement: ataxia.org/naf-calls-on-t… (1/3)

Last week, we were honored to win “Company of the Year” for a Medium-sized pharmaceutical company at @TheStevieAwards! 🎉 Together, we are driving innovation, shaping the future of medicine, & making a meaningful impact on patients’ lives. #BeBiohaven #StevieAwards

On Friday, we wrapped up an exciting week for Biohaven! CEO Vlad Coric, M.D., spoke with @jimcramer on @MadMoneyOnCNBC about Biohaven’s pipeline and upcoming milestones. #science $BHVN

🎉#BreakingNews: Biohaven is setting a new course! We’ve always been patient-centric and committed to delivering innovative life-changing treatments to help people live healthier lives. Learn more about today’s news here: ir.biohaven.com/news-releases/… #BeBiohaven

@rachsyme Meet Archie Bonkers! The size of a squirrel with the ❤️ of a giant

CastleKnight Management, a credit and equity hedge fund founded by Appaloosa alum Aaron Weitman, gained a net 64% in its master vehicle in its first full year: news.bloomberglaw.com/bankruptcy-law… w/ @ElizaHannon

Accurate.

@rbellini Congrats, Roberto!! Incredible news!

Very happy to share with you that the SOOTHE Phase 2b Trial hit all the objectives we set out for it! The two numbers we were all looking for: 34% pbo-adj reduction in cough frequency and ≤6.5% taste side effects. More details below. $BLU

@thegridkid my exact feeling to see this word excluded today 😔😔

Excited to demonstrate proof-of-mechanism in our Phase 1 study addressing AATD: first time a pharmacological chaperone has yielded increases in A1AT sufficient to potentially achieve > 11 micromolar protective threshold in individuals with PiZZ genotype. bit.ly/3Eu2oqm

One of the most interesting startups in the industry has been @centessa, assembled by the startup crew at Medicxi. @sciencescanner played a big role in that company, he'll talk about it at #EUBIO21 on Oct. 12. Tune in: endpts.com/care-about-rd-…

Today, we're pleased to announce positive topline data from the Phase 2a part of our proof-of-concept study evaluating SerpinPC in severe #hemophilia A and B patients. Read more here: bit.ly/3jRSVSh $CNTA

We are honored to ring today's @Nasdaq closing bell in celebration of our successful IPO! Congrats to our team, and thank you to our investors and everyone who has supported us in our mission to bring impactful medicines to patients. #NasdaqListed $CNTA

Now trading: We're proud to announce the pricing of our IPO. $CNTA is now on @Nasdaq. Thank you to everyone who has supported our mission! investors.centessa.com/news-releases/…

Dedicated to bringing asset centricity at scale to the world, #NasdaqListed $CNTA delivers impactful medicines to patients who desperately need them. Congratulations!